CN112512580A - Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途 - Google Patents

Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途 Download PDF

Info

Publication number
CN112512580A
CN112512580A CN201980049896.3A CN201980049896A CN112512580A CN 112512580 A CN112512580 A CN 112512580A CN 201980049896 A CN201980049896 A CN 201980049896A CN 112512580 A CN112512580 A CN 112512580A
Authority
CN
China
Prior art keywords
carcinoma
antibody
once
seq
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980049896.3A
Other languages
English (en)
Other versions
CN112512580B (zh
Inventor
张岚
蒋家骅
廖成
张连山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Suzhou Suncadia Biopharmaceuticals Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Suzhou Suncadia Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112512580A publication Critical patent/CN112512580A/zh
Application granted granted Critical
Publication of CN112512580B publication Critical patent/CN112512580B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

一种EZH2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途。具体而言，所述的EZH2抑制剂为式(I)所示化合物或其可药用盐，所述的免疫检查点抑制剂选自PD‑1抑制剂、PD‑L1抑制剂或CTLA‑4抑制剂。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201980049896.3A 2018-09-29 2019-09-27 Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途 Active CN112512580B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018111493570 2018-09-29
CN201811149357 2018-09-29
CN201811547685 2018-12-18
CN2018115476856 2018-12-18
PCT/CN2019/108535 WO2020063863A1 (zh) 2018-09-29 2019-09-27 Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途

Publications (2)

Publication Number Publication Date
CN112512580A true CN112512580A (zh) 2021-03-16
CN112512580B CN112512580B (zh) 2024-04-16

Family

ID=69953390

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980049896.3A Active CN112512580B (zh) 2018-09-29 2019-09-27 Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途

Country Status (3)

Country Link
CN (1) CN112512580B (zh)
TW (1) TW202027787A (zh)
WO (1) WO2020063863A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364231A (zh) * 2021-10-15 2022-11-22 北京大学第三医院（北京大学第三临床医学院） 一种增强ezh2抑制剂抗肿瘤作用的药物组合物及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202415655A (zh) 2022-06-13 2024-04-16 美商樹線生物科學公司 １，８—萘啶—２—酮異雙功能ｂｃｌ６降解劑
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
KR20240072936A (ko) * 2022-11-17 2024-05-24 인제대학교 산학협력단 Ezh2 저해제 및 항-pd-1 항체를 포함하는, 암의 예방 또는 치료용 약제학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017084494A1 (zh) * 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN108136011A (zh) * 2015-08-03 2018-06-08 星座制药公司 Ezh2抑制剂和调节性t细胞功能的调制

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018145095A1 (en) * 2017-02-06 2018-08-09 Bioventures, Llc Methods for predicting responsiveness of a cancer to an immunotherapeutic agent and methods of treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108136011A (zh) * 2015-08-03 2018-06-08 星座制药公司 Ezh2抑制剂和调节性t细胞功能的调制
WO2017084494A1 (zh) * 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364231A (zh) * 2021-10-15 2022-11-22 北京大学第三医院（北京大学第三临床医学院） 一种增强ezh2抑制剂抗肿瘤作用的药物组合物及其用途
CN115364231B (zh) * 2021-10-15 2023-11-17 北京大学第三医院（北京大学第三临床医学院） 一种增强ezh2抑制剂抗肿瘤作用的药物组合物及其用途

Also Published As

Publication number Publication date
CN112512580B (zh) 2024-04-16
TW202027787A (zh) 2020-08-01
WO2020063863A1 (zh) 2020-04-02

Similar Documents

Publication Publication Date Title
CN112512580B (zh) Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
CN109893654B (zh) Vegfr抑制剂治疗肿瘤的方法
US11498972B2 (en) Anti-OX40 antibody and use thereof
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN112007162B (zh) Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
WO2021063340A1 (zh) Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途
ZA200603804B (en) CD40 antibody formulation and methods
WO2018072743A1 (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
CN112168961A (zh) 治疗结直肠癌的联用药物组合物
CN111246881B (zh) Pd-1抗体用于治疗肿瘤的用途
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
CN109663130B (zh) Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
WO2021057764A1 (zh) Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途
CN113491769A (zh) 药物联合
WO2021063331A1 (zh) EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途
TW202214287A (zh) TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途
CN112512579B (zh) Tlr激动剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
CN110812485A (zh) 抗pd-1抗体联合化学疗法在制备治疗肿瘤的药物中的用途
CN112007034B (zh) Tlr激动剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
JP2022522328A (ja) Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与
CN111035759A (zh) 阿帕替尼与抗pd-1抗体联合在制备治疗软组织肉瘤的药物中的用途
CN110680919A (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗肿瘤的药物的用途
CN115894678B (zh) 一种干细胞细胞因子的制备方法及其在制备药品中的用途
CN116063478B (zh) 干细胞细胞因子的制备方法及其抗体联用的制药用途
WO2021203769A1 (zh) 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant